COMPASS Pathways PLC ADR (CMPS) News
Filter CMPS News Items
CMPS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CMPS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CMPS News From Around the Web
Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.
Compass Pathways Announces Pricing of Underwritten OfferingLONDON & NEW YORK, January 10, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares ("ADSs") and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant ("ADS Warrant") to purchase one |
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)LONDON, December 18, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024. |
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?Don't jump in without doing some research first. |
Compass Pathways to Participate in December Investor ConferencesLONDON & NEW YORK, November 25, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings: |
COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stakeKey Insights Institutions' substantial holdings in COMPASS Pathways implies that they have significant influence over... |
Compass Pathways to participate in Stifel 2024 Healthcare ConferenceLONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days |
Compass Pathways cuts 30% of workforce on Phase 3 trial delaysCompass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducing its workforce by approximately 30%, including eliminating some senior management positions, “to further focus the organization and its capital resources on successfully delivering the COMP360 program.” The company’s non-COMP360 preclinical efforts will be stopped and it is “exploring a potential externalization” for its digital health tools. Publish |
Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...Despite workforce reductions and trial delays, Compass Pathways PLC (CMPS) maintains a strong cash position and focuses on commercializing COMP360 for treatment-resistant depression. |
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call TranscriptCMPS earnings call for the period ending September 30, 2024. |
Compass delays anticipated psilocybin readout, cuts staffThe company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders. |